Zynebra Pharmaceuticals Inc. released data this week at a symposium by the Society for the Study of Behavioral Phenotypes (SSBP). The data concerns CBD and its effectiveness in the management of socio-behavioral symptoms. The symptoms were linked to three neuropsychiatric disorders.
The company said in a statement,
“Data indicates that patients with autism spectrum disorder, Fragile X Syndrome and 22q11.2 Deletion Syndrome, share a constellation of sociobehavioral symptoms and that the pharmacology of CBD is broad, continues to be defined, and may prove to be beneficial in addressing important behavioral symptoms of these conditions.”
The company also indicated that the data suggests that those with the three neuropsychiatric disorders have shared sociobehavioral symptoms such as anxiety, which can cause “social avoidant behavior, aggression, irritability, low attention and poor communication.”
Dr. Honey Heussler, an associate professor at the University of Queensland, Australia, also stated
“Those of us who care for patients and families contending with certain neuropsychiatric dysfunction understand that there are significant shared sociobehavioral symptoms between such disorders, though until now no review has been conducted to examine or clarify the overlap. These data on the shared behaviors between ASD, FXS and 22qDS are important to understanding disease impact, patient care, and the development of potential treatments. One such potential treatment being studied in well-controlled clinical trials is a proprietary gel formulation of CBD, which has diverse pharmacologic effects and may prove to be important in these neuropsychiatric disorders.”